Javascript must be enabled to continue!
Future of Uremic Toxin Management
View through CrossRef
During the progression of chronic kidney disease (CKD), the retention of uremic toxins plays a key role in the development of uremic syndrome. Knowledge about the nature and biological impact of uremic toxins has grown exponentially over the past decades. However, the science on reducing the concentration and effects of uremic toxins has not advanced in parallel. Additionally, the focus has remained for too long on dialysis strategies, which only benefit the small fraction of people with CKD who suffer from advanced kidney disease, whereas uremic toxicity effects are only partially prevented. This article reviews recent research on alternative methods to counteract uremic toxicity, emphasizing options that are also beneficial in the earlier stages of CKD, with a focus on both established methods and approaches which are still under investigation or at the experimental stage. We will consequently discuss the preservation of kidney function, the prevention of cardiovascular damage, gastro-intestinal interventions, including diet and biotics, and pharmacologic interventions. In the final part, we also review alternative options for extracorporeal uremic toxin removal. The future will reveal which of these options are valid for further development and evidence-based assessment, hopefully leading to a more sustainable treatment model for CKD than the current one.
Title: Future of Uremic Toxin Management
Description:
During the progression of chronic kidney disease (CKD), the retention of uremic toxins plays a key role in the development of uremic syndrome.
Knowledge about the nature and biological impact of uremic toxins has grown exponentially over the past decades.
However, the science on reducing the concentration and effects of uremic toxins has not advanced in parallel.
Additionally, the focus has remained for too long on dialysis strategies, which only benefit the small fraction of people with CKD who suffer from advanced kidney disease, whereas uremic toxicity effects are only partially prevented.
This article reviews recent research on alternative methods to counteract uremic toxicity, emphasizing options that are also beneficial in the earlier stages of CKD, with a focus on both established methods and approaches which are still under investigation or at the experimental stage.
We will consequently discuss the preservation of kidney function, the prevention of cardiovascular damage, gastro-intestinal interventions, including diet and biotics, and pharmacologic interventions.
In the final part, we also review alternative options for extracorporeal uremic toxin removal.
The future will reveal which of these options are valid for further development and evidence-based assessment, hopefully leading to a more sustainable treatment model for CKD than the current one.
Related Results
Encefalopati uremikum pada pasien gagal ginjal: Laporan kasus
Encefalopati uremikum pada pasien gagal ginjal: Laporan kasus
Background: Patients with kidney failure often experience clinical symptoms related to fluid and electrolyte imbalance, anemia, malnutrition, and gastrointestinal disorders. One of...
Identification of Small Molecule Inhibitors of Clostridium perfringens ε-Toxin Cytotoxicity Using a Cell-Based High-Throughput Screen
Identification of Small Molecule Inhibitors of Clostridium perfringens ε-Toxin Cytotoxicity Using a Cell-Based High-Throughput Screen
The Clostridium perfringens epsilon toxin, a select agent, is responsible for a severe, often fatal enterotoxemia characterized by edema in the heart, lungs, kidney, and brain. The...
Abstract 690: Endothelial-Specific Krüppel-Like Factor 2 Inactivation Promotes Endothelial Dysfunction in the Setting of Uremia
Abstract 690: Endothelial-Specific Krüppel-Like Factor 2 Inactivation Promotes Endothelial Dysfunction in the Setting of Uremia
Background:
Uremic solutes that accumulate in end-stage renal disease (ESRD) contribute to endothelial dysfunction and subsequent cardiovascular disease in ESRD patient...
Exploration on the Research Progress of Traditional Chinese Medicine in Treating Uremic Cardiomyopathy based on Cardiomyocyte Protection
Exploration on the Research Progress of Traditional Chinese Medicine in Treating Uremic Cardiomyopathy based on Cardiomyocyte Protection
Uremic cardiomyopathy is an important complication that affects the quality of life and prognosis of patients with chronic kidney disease. The damage to myocardial cells is a major...
Food-Derived Uremic Toxins in Chronic Kidney Disease
Food-Derived Uremic Toxins in Chronic Kidney Disease
Patients with chronic kidney disease (CKD) have a higher cardiovascular risk compared to the average population, and this is partially due to the plasma accumulation of solutes kno...
Clostridium perfringens Delta-Toxin Damages the Mouse Small Intestine
Clostridium perfringens Delta-Toxin Damages the Mouse Small Intestine
Clostridium perfringens strains B and C cause fatal intestinal diseases in animals. The secreted pore-forming toxin delta-toxin is one of the virulence factors of the strains, but ...
C. difficile toxin A increases intestinal permeability and induces Cl- secretion
C. difficile toxin A increases intestinal permeability and induces Cl- secretion
Mucosal sheets of guinea pig ileum mounted in Ussing chambers were used to determine effects of highly purified Clostridium difficile toxin A on intestinal structure and barrier fu...
Analysis of Mechanisms of T-2 Toxin Toxicity Using Yeast DNA Microarrays
Analysis of Mechanisms of T-2 Toxin Toxicity Using Yeast DNA Microarrays
T-2 toxin is a mycotoxin that belongs to a group of type A tricothecenes found in agricultural products. The cytotoxicity of T-2 toxin was characterized by analysis of the yeast tr...

